Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Clinical Importance of Right Ventricular Involvement in Mild Dilated Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Paving the Path to Universal Health Coverage: Incorporating Rehabilitation Into Primary Healthcare.

Annals of rehabilitation medicine·2026
Same author

Genetic Association of Circulating Proteins and Gene Transcripts With Spontaneous Coronary Artery Dissection.

Circulation. Genomic and precision medicine·2026
Same author

Benefits and Drawbacks of Teleneurosurgery in Low- and Middle-Income Countries: A Scoping Review.

Acta neurologica Taiwanica·2025
Same author

A double-blind, randomized placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathy.

European heart journal. Cardiovascular Imaging·2025
Same author

Efficacy and safety of microaxial flow pump in infarct-related cardiogenic shock: a meta-analysis.

Archives of medical sciences. Atherosclerotic diseases·2025

Related Experiment Video

Updated: Jun 29, 2025

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.3K

Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift?

Saad Javed1,2, Brian P Halliday1,2

  • 1National Heart and Lung Institute, Imperial College London, UK.

Cambridge Prisms. Precision Medicine
|March 29, 2024
PubMed
Summary

Precision medicine offers personalized cardiomyopathy treatments, improving outcomes by targeting therapies and reducing interventions. Future research will focus on early disease mechanisms for prevention, shifting care from symptom management to proactive health.

Keywords:
cardiovascular geneticsdilated cardiomyopathygene therapyheart failureprecision medicine

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

Area of Science:

  • Cardiology
  • Genomics
  • Precision Medicine

Background:

  • Dilated cardiomyopathy (DCM) is a primary cause of heart failure worldwide, characterized by left ventricular dilation and dysfunction.
  • Genomic medicine advances have significantly improved understanding of DCM's genetic underpinnings.
  • Variable expressivity of rare genetic variants is influenced by common genetic variations and environmental factors, complicating individualized treatment.

Purpose of the Study:

  • To explore the potential of precision medicine in improving patient outcomes for cardiomyopathies.
  • To investigate genotype-specific disease mechanisms in DCM through advanced multi-omics and imaging.
  • To shift the focus towards early disease detection and prevention strategies for cardiomyopathies.

Main Methods:

  • Leveraging advances in genomic medicine to understand DCM's genetic architecture.
  • Employing advanced cardiac imaging and multi-omics approaches to elucidate genotype-specific disease mechanisms.
  • Investigating the impact of common genetic variation and environmental factors on disease expression.

Main Results:

  • Precision medicine promises to enhance patient outcomes and reduce healthcare costs by tailoring treatments.
  • Understanding genetic variations is crucial for developing novel, targeted therapies for DCM.
  • Identifying early disease mechanisms is key to enabling a paradigm shift in cardiovascular care.

Conclusions:

  • Precision medicine in cardiomyopathies can optimize treatment efficacy and minimize unnecessary interventions.
  • Further research into early disease mechanisms is essential for transitioning from disease management to prevention.
  • Integrating genomic insights with clinical approaches will drive personalized strategies for heart failure prevention and treatment.